Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acquired Hyperostosis Syndrome Therapy
Research from University of Barcelona has provided new data on acquired hyperostosis syndrome therapy
May 18th, 2008
A new study, 'Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature,' is now available. According to a study from Barcelona, Spain, "To analyze the clinical efficacy of anti-tumor necrosis factor (TNF)-alpha therapy in the SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. We describe 2 new cases with ilium osteitis as the main SAPHO syndrome feature and review reported cases treated with anti-TNF-alpha." "A literature search of SAPHO syndrome cases treated with TNF-alpha blocking therapy with special emphasis on osteoarticular and skin responses was performed. Eighteen cases were...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-18)
|
